These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25524801)

  • 1. CDK4/6 inhibitors in luminal breast cancer.
    Gnant M; Steger GG; Bartsch R
    Lancet Oncol; 2015 Jan; 16(1):2-3. PubMed ID: 25524801
    [No Abstract]   [Full Text] [Related]  

  • 2. Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.
    Fang H; Huang D; Yang F; Guan X
    Breast Cancer Res Treat; 2018 Apr; 168(2):287-297. PubMed ID: 29236235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer.
    Weiss J; Afghahi A; Shagisultanova E; Diamond JR
    Oncology (Williston Park); 2018 Oct; 32(10):513-5. PubMed ID: 30334242
    [No Abstract]   [Full Text] [Related]  

  • 4. Palbociclib ups PFS in HER2-/ER+ breast cancer.
    Cancer Discov; 2014 Jun; 4(6):624-5. PubMed ID: 24891344
    [No Abstract]   [Full Text] [Related]  

  • 5. Overall survival in first-line HR+/HER2- advanced breast cancer in the era of CDK4/6 inhibitors.
    Sánchez-Bayona R; Oliveira M
    Ann Oncol; 2024 Aug; 35(8):689-691. PubMed ID: 39048261
    [No Abstract]   [Full Text] [Related]  

  • 6. CDK4/6 inhibitors for hormone receptor-positive HER2-negative metastatic breast cancer: does one size fit all?
    Fedele P; Cinieri S
    Future Med Chem; 2019 Jun; 11(11):1237-1239. PubMed ID: 31179740
    [No Abstract]   [Full Text] [Related]  

  • 7. CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer.
    Migliaccio I; Bonechi M; McCartney A; Guarducci C; Benelli M; Biganzoli L; Di Leo A; Malorni L
    Cancer Treat Rev; 2021 Feb; 93():102136. PubMed ID: 33360919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDK4/6 Inhibitors for Advanced Hormone Receptor-Positive Breast Cancer, 2019 and Beyond.
    Layman RM
    J Natl Compr Canc Netw; 2019 Feb; 17(2):190-192. PubMed ID: 30787131
    [No Abstract]   [Full Text] [Related]  

  • 9. The Therapeutic Effects of Specific CDK4/6-inhibitors in Treating HR-positive, HER2-negative Advanced Breast Cancer.
    Luis M
    Klin Onkol; 2018; 31(4):305-308. PubMed ID: 30541316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?
    Shah M; Nunes MR; Stearns V
    Oncology (Williston Park); 2018 May; 32(5):216-22. PubMed ID: 29847850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer.
    Cruz M; Reinert T; Cristofanilli M
    Clin Pharmacol Ther; 2018 Jun; 103(6):1009-1019. PubMed ID: 29226311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of CDK4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER-2- ABC Patients: A Systematic Review and Meta-Analysis.
    Li Y; Li L; Du Q; Li Y; Yang H; Li Q
    Cancer Invest; 2021 May; 39(5):369-378. PubMed ID: 33886387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin-dependent kinase 4/6 inhibition in the treatment of hormone receptor-positive breast cancer.
    Rugo HS
    Clin Adv Hematol Oncol; 2019 Oct; 17(10):555-558. PubMed ID: 31730581
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
    Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
    Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors.
    McCartney A; Malorni L
    Br J Cancer; 2020 Jul; 123(2):176-177. PubMed ID: 32382111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer.
    Cejalvo JM; Pascual T; Fernández-Martínez A; Brasó-Maristany F; Gomis RR; Perou CM; Muñoz M; Prat A
    Cancer Treat Rev; 2018 Jun; 67():63-70. PubMed ID: 29763779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
    Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM
    Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER²⁺ Breast Cancer.
    Malumbres M
    Cancer Cell; 2016 Mar; 29(3):243-244. PubMed ID: 26977873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding divergent trial results of adjuvant CDK4/6 inhibitors for early stage breast cancer.
    Cunningham NC; Turner NC
    Cancer Cell; 2021 Mar; 39(3):307-309. PubMed ID: 33689702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
    Shah AN; Cristofanilli M
    Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.